PharmEasy acquires Aknamed in $180-$190 million stock deal

The acquisition, which is similar to its purchase of Thyrocare in June, is part of the Mumbai-based company’s plans to position itself as a broader online healthcare firm, diversifying from being just an online medicine delivery platform.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2XkUpLT
via IFTTT

0 comments:

Post a Comment